Penpulimab
Monoclonal antibody
Also known as AK105
Evidence outlook
Approved: Nasopharyngeal Carcinoma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Non-Small Cell Lung Cancer · Phase 3 · investigational in the USHepatocellular Carcinoma · Phase 3 · investigational in the US
Also approved (2)
- In combination with chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC)
- In combination with chemotherapy, first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04974398 NCT04974398 · Nasopharyngeal Carcinoma Patients were randomly assigned to penpulimab or a matching placebo with patients, doctors and assessors all blinded, and the trial met its primary endpoint, progression-free survival judged by blinded central review. A power calculation was reported, and 291 patients were randomized against a planned 278. Registry: NCT04974398 | 3 | Progression-free survival (PFS) (Up to 2 years) 2026-02-23 | Results not posted; external-source review pending | Reliable signal | link ↗ |
View 1 more trial
NCT03866967 NCT03866967 · Nasopharyngeal Carcinoma Registry: NCT03866967 | 2 | Objective response rate (ORR) assessed by IRRC per RECIST v1.1 for anti-tumor activity in the Full Analysis Set (FAS) population (up to 2 years) 2021-03-13 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (47)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (2)
What this study did
What this study did
Early phase / not applicable (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (2)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 2 (1)
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
Other PD-1 drugs
Cemiplimab, Dostarlimab, Nivolumab, Opdivo Qvantig, Pembrolizumab and 21 more. Compare all 27 PD-1 drugs
This mechanism is crowded: 26 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Hepatocellular Carcinoma: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Penpulimab: this drug | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | not yet graded | No reviewed efficacy summary in this indication | |
| Cabozantinib | Approved | Small molecule | MET / VEGFR / AXL / RET (multi-kinase) | Partial signal | NCT01908426: Overall Survival (OS) (Up to 45 months): Cabozantinib (XL184) 10.2 months (95% CI 9.1 to 12) | Placebo 8 months (95% CI 6.8 to 9.4) | |
| Durvalumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Ipilimumab | Approved | Monoclonal antibody | CTLA-4 antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Nivolumab | Approved | Monoclonal antibody | PD-1 | Partial signal | No reviewed efficacy summary in this indication | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Reliable signal | NCT03062358: Overall Survival (OS) (Up to approximately 4 years): Pembrolizumab + BSC 14.6 Months (95% CI 12.6 to 18) | Placebo + BSC 13 Months (95% CI 10.5 to 15.1) | |
| Ramucirumab | Approved | Monoclonal antibody | VEGFR2 | Partial signal | NCT02435433: Overall Survival (OS) (From Date of Randomization to Death from Any Cause (Up to 28 Months)): Ramucirumab + Best Supportive Care (BSC) 8.51 Months (95% CI 7 to 10.58) | Placebo + BSC 7.29 Months (95% CI 5.42 to 9.07) | |
| Regorafenib | Approved | Small molecule | Multi-kinase inhibitor (VEGFR/PDGFR/KIT) | not yet graded | No reviewed efficacy summary in this indication | |
| Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs) | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Tremelimumab | Approved | Monoclonal antibody | CTLA-4 | Partial signal | No reviewed efficacy summary in this indication | |
| Amezalpat | Phase 3 | Small molecule | PPARα (peroxisome proliferator-activated receptor alpha) | not yet graded | No reviewed efficacy summary in this indication | |
| Apatinib | Phase 3 | Small molecule | VEGFR2 | not yet graded | No reviewed efficacy summary in this indication | |
| BGB-B2033 | Phase 3 | Multispecific antibody | GPC3 (glypican-3) x 4-1BB (CD137) | not yet graded | No reviewed efficacy summary in this indication | |
| Cadonilimab | Phase 3 | Multispecific antibody | PD-1×CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Camrelizumab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Iparomlimab (QL1604) | Phase 3(overall) | Monoclonal antibody | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| JS207 | Phase 3 | Multispecific antibody | PD-1 + VEGFA | not yet graded | No reviewed efficacy summary in this indication | |
| Namodenoson | Phase 3 | — | Adenosine A3 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Nilvanstomig | Phase 3 | Biologic (subtype unspecified) | PD-1 and TIGIT | not yet graded | No reviewed efficacy summary in this indication | |
| Pegargiminase | Phase 3 | Protein / enzyme therapeutic | Arginine-depleting pegylated arginine deiminase | not yet graded | No reviewed efficacy summary in this indication | |
| Rilvegostomig | Phase 3 | Multispecific antibody | PD-1 and TIGIT | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-3045 | Phase 2(overall) | Undisclosed | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| RYZ801 | Phase 1/2 | Radiopharmaceutical | — | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-324 | Phase 1 | Antibody–drug conjugate | Glypican-3 (GPC3) / Topoisomerase I | not yet graded | No reviewed efficacy summary in this indication | |
| Bmab1700 | Phase 1(overall) | Monoclonal antibody | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| CRX100 | Phase 1 | Cell therapy | Cell-based oncolytic virus immunotherapy | not yet graded | No reviewed efficacy summary in this indication | |
| SENTI-301A | Phase 1 | Cell therapy | GPC3 (CAR-NK, calibrated IL-15) | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-2524 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| AZD7003 | —(overall) | Cell therapy | Glypican-3 (GPC3) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
17 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(9 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Penpulimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.